{"classes":[{"categories":[{"measurements":[{"groupId":"OG001","lowerLimit":"40.7","upperLimit":"239.7","value":"53.7"},{"groupId":"OG002","lowerLimit":"22.4","upperLimit":"228.1","value":"25.1"},{"groupId":"OG003","lowerLimit":"12.1","upperLimit":"138.4","value":"90.3"},{"groupId":"OG004","lowerLimit":"18.3","upperLimit":"121.0","value":"55.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"6"}],"units":"Participants"}],"description":"Duration of overall response in weeks (DoR) applies only to patients whose best overall response is CR or PR. The start date is the date of first documented response (CR or PR) and the end date is the date of event defined as first documented disease progression or death due to underlying cancer.","dispersionType":"Full Range","groups":[{"description":"Participants received 5x10e6 pfu TG4001 subcutaneously along with 10 mg/kg avelumab intravenously until disease progression, unacceptable toxicity, participant withdrawal from study for any reason.","id":"OG000","title":"Phase I - TG4001 5x10e6 Pfu Avelumab"},{"description":"Participants received 5x10e7 pfu TG4001 subcutaneously along with 10 mg/kg avelumab intravenously until disease progression, unacceptable toxicity, participant withdrawal from study for any reason.","id":"OG001","title":"Phase I - TG4001 5x10e7 Pfu Avelumab"},{"description":"Participants received 5x10e7 pfu TG4001 subcutaneously along with 10 mg/kg avelumab intravenously until disease progression, unacceptable toxicity, participant withdrawal from study for any reason.","id":"OG002","title":"Phase II Part 1 - TG4001 5x10e7 Pfu + Avelumab"},{"description":"Participants received 5x10e7 pfu TG4001 subcutaneously along with 800 mg avelumab intravenously until disease progression, unacceptable toxicity, participant withdrawal from study for any reason.","id":"OG003","title":"Phase II Part 2 - Cohort A - Participants Without Liver Metastases - TG4001 5x10e7 Pfu + Avelumab"},{"description":"Participants received 800 mg avelumab intravenously until disease progression, unacceptable toxicity, participant withdrawal from study for any reason.","id":"OG004","title":"Phase II Part 2 - Cohort A - Participants Without Liver Metastases - Avelumab"}],"paramType":"MEDIAN","populationDescription":"For phase Ib, phase II part 1 and phase II part 2 Cohort A, analysis population consists of all included participants who were dosed with IMP(s) according to treatment allocation and who have a confirmed response according to RECIST1.1.\n\nFor Phase II part 2 Cohort B, the outcome measure duration of overall response has not been defined as secondary endpoint. Therefore Phase II part 2 cohort B is not included in the analysis population.","reportingStatus":"POSTED","timeFrame":"From treatment start Phase Ib, Phase II part 1 / from randomization Phase II part 2 Cohort A : every 6 weeks for the first 9 months, then every 12 weeks through study completion, for an average of 2.5 years.","title":"Duration of Overall Response (DoR): Phase Ib, Phase II Part 1, Phase II Part 2 Cohort A","type":"SECONDARY","unitOfMeasure":"Weeks"}